Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
REDWOOD CITY, Calif. - Seer, Inc. (NASDAQ:SEER), a company specializing in proteomic analysis with a market capitalization of $117 million and strong liquidity position, announced the launch of its new Proteograph Product Suite, which includes the Proteograph ONE Assay and SP200 Automation Instrument. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt and a current ratio of 19.34x. This suite is designed to enhance the scalability, efficiency, and affordability of large-scale proteomic studies, which have traditionally been limited by high costs and low throughput.
The product suite, which will be showcased at the American Society for Mass Spectrometry (ASMS) annual conference, is said to process over 1,000 samples per week using a single SP200 instrument. This marks a significant increase in throughput capability without compromising performance. Additionally, the new workflow is expected to reduce the cost of proteomic analysis by about 60% compared to the initial Proteograph Product Suite launched in 2021. While the company shows promise in innovation, InvestingPro analysis indicates rapid cash burn, with negative EBITDA of $89.41 million in the last twelve months. Get access to 7 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.
Seer’s latest development aims to enable population-scale studies in biomarker discovery and disease research by addressing historical challenges in the field. The company claims that the suite can identify up to ten times more proteins than traditional mass spectrometry workflows.
At the ASMS 2025 Annual Conference, Seer and its collaborators will present new scientific data, including studies on Alzheimer’s disease, cancer, and drug development. Notably, Professors Josh Coon and Gary Patti will share their experiences with the Proteograph ONE workflow in a breakfast seminar.
The new Proteograph Product Suite will be commercially available starting June 1. It can be accessed through instrument and kit purchases or as a service via the Seer Technology Access Center (STAC). Trading near $2 per share, Seer appears undervalued according to InvestingPro Fair Value calculations, though analysts don’t expect profitability this year. Discover detailed valuation metrics and 1,400+ comprehensive Pro Research Reports by subscribing to InvestingPro.
Seer, Inc. emphasizes that its products are for research use only and not intended for diagnostic procedures. The information about the launch and the new Proteograph Product Suite is based on a press release statement.
In other recent news, Seer Inc. reported a substantial revenue increase of 37% year-over-year for the first quarter of 2025, amounting to $4.2 million. Despite facing a net loss of $19.9 million, the company’s strategic initiatives, including product innovations and partnerships, have contributed to this growth. Notably, Seer expanded its partnership with Thermo Fisher Scientific, enhancing its market reach. The company also launched a new application for its Proteograph platform, which is expected to drive further growth. Seer’s financial outlook for the full year 2025 anticipates revenue between $17 million and $18 million, representing a 24% growth year-over-year. Analysts from JPMorgan have shown interest in Seer’s large-scale study with Discovery Life Sciences, which involves a significant 10,000 sample cohort. The company remains cautious due to macroeconomic uncertainties, including potential tariffs and government funding challenges. However, Seer’s management expresses confidence in achieving cash flow breakeven with its current cash reserves of $285 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.